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Abstract 
Purpose. To evaluate the changes in living donor liver transplantations (LDLTs) over 
the last 10 years, we analyzed our experience of performing LDLT in a single center. 
Methods and Results. We performed 73 LDLTs over the 10 years between 1997 and 
2007 in Nagasaki University Hospital, Japan. Initially, from 1997 to 2003, LDLT was 
performed for pediatric patients; then, between 2004 and 2007, adult-to-adult LDLT was 
introduced, primarily for hepatocellular carcinoma (HCC) in liver cirrhosis. We also 
began performing LDLTs for adults with ABO-incompatible blood type combination in 
the latter period. As the number of adult-to-adult LDLTs increased, left-sided grafts 
became first choice for these patients. Survival rates were 88.3%, 77.2%, 70.2% at 1, 3 
and 5 years respectively. There was a relatively low incidence of arterial complications, 
and although the incidence of biliary complications was high initially, it decreased with 
experience. Likewise, the operative time, blood loss, and hospital stay after LDLT also 
improved remarkably.  
Conclusion. Over the last 10 years, the indications for, and operative techniques used in 
LDLT have changed dramatically, even in a single center in Japan. 
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Introduction 
Since the first living donor liver transplantation (LDLT) was reported in 1989, this 
operation has gained widespread recognition as a life-saving treatment, especially in 
Japan, where deceased donor liver transplantation (DDLT) is not yet accepted. 1, 2 We 
started our liver transplant program in August, 1997 and by August 2007, we had 
performed 73 LDLTs. Although the liver transplant registry in Japan reports the details 
of LDLTs annually in the Japanese literature, a detailed analysis to define the changes in 
LDLT over the past 10 years would be difficult based on a nation-wide cohort. Thus, we 
conducted a retrospective study on LDLT in a single center to evaluate the changes and 
evolution in this 10-year period. 
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Patients and Methods 
Subjects 
The subjects of this retrospective review were 73 patients who underwent LDLT 
between August, 1997 and August, 2007 at Nagasaki University Hospital, Japan. The 
median follow-up of the patients after primary LDLT was 30 months (0-123 months). 
Adult patients are defined as those over 16 years old. 
Methods 
    All partial liver grafts were preserved in University of Wisconsin solution and 
implanted using a piggy-back technique. Surgeons experienced in microscopic surgery 
anastomosed all of the hepatic arteries with the aid of an operative microscope. In 
general, graft selection was based on the results of a volumetric study using computed 
tomography (CT) to obtain a ratio of graft volume to standard liver volume of more than 
35% in the recipients.3 
     A dual or triple immunosuppressive regimen was used, which included 
Tacrolimus or Cyclosporine A, prednisolone, and micophenolate mofetil. Patients with 
compromised renal function were given, induction therapy with IL-2 antibodies.4 Only 
biopsy-proven rejections were treated if clinical and laboratory signs mandated steroid 
bolus treatment. Steroid-resistant rejections were treated with OKT3.  
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     The following variables were studied: gender, age, original liver disease, 
indications for LDLT, Child-Pugh and Model for End-Stage Liver Disease (MELD) 
score at time of LDLT, ABO compatibility, operative blood loss, operative time, and 
graft type. 
     Because the Japanese National Health Insurance policy was changed in January, 
2004, to cover most adult recipients, including those with hepatocellular carcinoma 
(HCC) within the Milan criteria, we analyzed the indications for LDLT before and after 
January, 2004. Furthermore, as a chief surgeon was appointed for all LDLTs in April, 
2005, we compared the operative variables before and after April, 2005. 
     Overall patient survival was defined as the time in months between LDLT and the 
death of the patient or the end of the study period, on August 31, 2007. The median 
follow-up of patients was 29 months (0-120 months) for adults and 35 months (0-123 
months) for children. 
 
Statistics 
     Patient survival was calculated with the Kaplan-Meier method. The Log-rank test 
was used to compare survival between groups. Operative variables were compared with 
a non-parametric test. P-values less than 0.05 were considered significant. 




During the second part of the study period, from 2004 to 2007 (n=45), more 
adult-to-adult LDLTs were performed than in the first part, from 1997 to 2003 (n=28), 
because HCC in a cirrhotic liver caused by viral hepatitis became the main indication 
for LDLT (Table 1, Fig. 1). Accordingly, the donor population changed from “parent to 
child” to “child to parent”. We also began to perform ABO-incompatible combination 
LRLTs for adult patients (Table 1). Moreover, as the number of adult-to-adult LRLTs 
increased, left-sided grafts became the first choice in these cases to ensure the safety of 
donor surgery. 
     The changes in operative details and management in adult-to-adult LDLTs are 
summarized in Table 2. Since pediatric LDLT presents different operative and 
management challenges than adult LDLT, only cases of adult-to-adult LDLT were 
compared in this regard. Over the 10 years, blood loss, operative time, and hospital stay 
improved significantly with better management and advances in operative procedures 
(p<0.05). 
     The overall patient survival rates 1, 3 and 5 years after LDLT were 88.3%, 77.2%, 
70.2%,, respectively. There was no difference in patient survival between the adult and 
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pediatric recipients (Fig. 3). Portal venous complications occurred in two (2.7 %) 
patients in the early phase after LDLT, mainly caused by mechanical and immunological 
events, whereas in late phase, six (8.2 %) patients suffered complications related to 
stenosis and thrombus in a portal vein, which were primarily treated with 
anticoagulation and balloon dilation (Table 3).  
     The results of arterial anastomosis are summarized in Table 4. Anatomical arterial 
anastomosis of a graft hepatic artery to a recipient hepatic artery was performed in 65 
patients (86.6%), whereas a nonanatomical anastomosis of the side of a recipient artery 
other than a hepatic artery was performed in ten (13.4%) patients. Arterial complications 
occurred in six (8.2%) patients, including hepatic artery thrombus (HAT) in three 
(4.1%). Re-anastomosis was performed in five patients, but one these patients died of a 
second HAT. Hepatic arterial rupture occurred in one patient, as a result of a 
pseudoaneurysm developing after a fungal infection at the anastomotic site. 
     The methods of biliary reconstruction and their complications are shown in Table 
5. Duct-to-duct anastomosis was performed in 53 (72.6%) patients, most of whom were 
adults. Biliary complications developed in 14 (19.1%) patients, including anastomotic 
stricture in 10 (13.7%) patients.  
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Discussion 
Our results show that the indications for LDLT changed dramatically after January 2004 
in accordance with the amendments to the National Health Insurance policy in Japan: 
from being reserved exclusively for pediatric patients and patients with acute disorders 
to include adult patients with chronic liver failure; most notably, those with HCC 
secondary to viral hepatitis. Accordingly, the relationship between the living donor and 
the recipient also changed over this 10-year period. With the extended indications of 
LDLT for HCC and other chronic liver diseases, the sons and daughters of about half 
these recipients have become partial liver donors to save their parents. 
     The 5-year survival rate after LDLT has improved to 70%.1, 5 Moreover, in April, 
2005, our hospital appointed a senior surgeon to head the liver transplant team. This 
surgeon is responsible for both recipient and donor surgery and a dedicated LDLT team 
has developed, which includes surgeons, hepatologists, and nurses, as well as case 
coordinators. As a team, we have succeeded in reducing the operative time, and blood 
loss, and consequently, the hospital stay after LDLT. Furthermore, the operative 
technique has been adapted based on updated information from the world literature; for 
example in relation to the reconstruction of tributaries of the middle hepatic vein,6-8 or 
bile duct assessment in the donor 9-11 Interestingly, because of the broader indications 
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for LDLT, which include HCC rather than end-stage liver cirrhosis in the latter period, 
the MELD score of the recipients has become lower than in the former period, which 
might be a contributing factor to the lower blood loss during surgery.  
     Improved antiviral therapy has also contributed to the favorable outcome of 
LDLT; including lamivudine, pegylated interferon, and the recent advent of 
entecavir.12,13  There were remarkably more patients with viral-related liver disease in 
latter period of this study than in the former period , at 33 vs. 5, (13 vs 2 with HBV and 
25 vs. 3 with HCV), respectively; however, a comparison in survival between the 
periods was not performed and awaits a longer observation period. 
     An increase in the number of LDLTs performed successfully in ABO blood type- 
incompatible patients was achieved with the advent of the anti CD20 antibody 
(rituximab) to eradicate B cells, which produce the anti-donor blood type antibody, and 
the development of local infusion therapy in Japan.14,15  On account of these therapies, 
the outcomes of LDLT using an ABO-incompatible partial graft have become close to 
those obtained with an ABO-compatible graft. Naturally, the number of 
ABO-incompatible LDLTs performed will increase because of the shortage of deceased 
donor LTs, based on the feasibility of preparing recipients for elective LDLT, by 
administering Rituximab. 
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     The higher incidence of portal venous complications in LDLT may be attributable 
to the smaller graft size than in whole-liver LT.16 Late complications developed in six 
(8.2%) of our patients, but most were treated with anticoagulants and radiological 
intervention. Three of the four patients with portal venous stenosis were operated on in 
the former period and had size mismatch in the portal vein between the recipient and 
donor livers.  The other recipient had predisposing portal venous disease in the form of 
a portal venous aneurysm. Although portal venous complications in pediatric patients 
have been studied in detail and the incidence calculated at approximately 8% after 
LDLT17, size-mismatched LDLT in adults needs to be analyzed.  
     Surgery with the aid of an operative microscope has minimized the risks of 
arterial complications, even though the diameter of each anastomosis is much smaller in 
LDLT than in DDLT.18 Moreover, because the arteries are so short, non-anatomical 
anastomosis is more common in LDLT than in DDLT; however, the short arteries do not 
increase the incidence of HAT or other problems in arterial anastomosis. HAT requiring 
reanastomosis developed in three (4.1%) of our patients and this incidence is 
comparable with those in previous reports on LDLT. 19 
    Biliary complications are said to be the “Achilles’ heel” of LDLT; supported by the 
fact that they occurred in 19% of our patients. However, with advances in operative 
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procedures, in both donors and recipients, and a better understanding of the anatomy, 
the incidence of biliary complications has been decreasing. Thus, our policy to perform 
duct-to-duct anastomosis if possible is justified, although the need for tube splints 
awaits further clinical trials. 
     In conclusion, the indications for LDLT and its operative techniques have 
changed dramatically over the last 10 years, even in a single center in Japan. 
Nevertheless, further refinement is needed for better postoperative morbidity and 
mortality. 
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Figure Legends 
Fig.1 Changes in the indications for living donor liver transplantation over 10 
years 
LC-B, liver cirrhosis due to hepatitis B; LC-C, liver cirrhosis due to hepatitis C; 
HCC, hepatocellular carcinoma; BA, biliary atrasia; FHF, fulminant hepatic 
failure; LC-Alcohol, liver cirrhosis due to alcohol; PBC, primary biliary cirrhosis; 
PSC, primary sclerosing cholangitis; SBC, secondary biliary cirrhosis, LC-NBNC, 
liver cirrhosis without hepatitis B or C 
Fig. 2 Changes in the relationship between donors and recipients of living donor 
liver transplantation 
Fig. 3 Patient survival after living donor liver transplantation 
 
 
Table 1. Summary of living donor liver transplant recipients and procedures
Total Aug, 1997 – Dec, 2003   Jan, 2004 – Jul, 2007 p
Number 73 28 45
Adult 64 (87.6%) 20 (71.5%) 44 (97.8%) n.s.
Pediatric 9 (12.3%) 8 (28.5%) 1 (2.2%)
Age 54(0-68) 37.5 (0-63) 56 (11-68)             <0.05
Gender (M/F) 42/31 13/15 22/17 n.s.
ABO blood type combination
identical 51 (70.0%) 21 (75.0%) 30 (66.6%) n.s.
compatible 13 (17.8%) 5 (17.9%) 8 (17.7%)
incompatible 9 (12.3%) 2 (7.1%) 7 (15.5%)
MELD score 18(7-41) 22.5(11-41) 17(7-36) n.s.
Graft type
right sided graft 47 (64.3%) 19 (67.9%) 28 (62.2%) n.s.
left sided graft 26 (35.6%) 9 (32.1%) 17 (37.7%)
MELD, Model for End-Stage Liver Disease; n.s., not significant 
Aug, 1997-March, 2005          Apr, 2005 – Jul, 2007
(n=34) (n=30) p
Age (years old) 52 (16-65) 57 (16-68) n.s.
Gender (M/F) 22/12 18/12 n.s.
Child-Pugh score 11(7-14) 10.5 (7-12) n.s.
Blood loss (g) 12,270 (1,230-121,348) 5,805 (1,100-47,530)        <0.05
Op time (minutes) 1099.5 (666-1,757) 899 (726-1,237) <0.05
In hospital mortality 4 (11.7%) 2 (6.5%) n.s.
Admission days 52 (21-388) 37 (18-126) <0.05
Table 2. Changes in the surgical techniques and management of  adult-to-adult 
living donor liver transplantation
Op time, operation time;  n.s.,  not significant 
Primary disease GV/SLV PV flow Pathogenesis Treatment Outcomes
1. 60 F   LC-C/HCC 47% hypoperfusion compressed (hematoma) surgery survived
2. 57 M  LC-B/HCC 36.2% interrupted kinked (positional) surgery survived
Table 3. Portal venous complications after living donor liver transplantation
Primary disease PV complication Treatment Outcome
1. 16M FHF stenosis balloon dilation survived
2. 61M LC-B stenosis anticoaglation survived
3. 6F Biliary atrasia stenosis＋thrombus balloon dilation died
4. 61F LC-C/HCC stenosis＋thrombus tPA +baloon dilation＋ anticoaglation survived
Portal vein aneurysm
5. 61F LC-C/HCC thrombus（post splenectomy） anticoaglation survived




GV/SLV, graft volume/standard liver volume; PV flow, portal venous flow; FHF, fulminant hepatic failure;
LC-B, liver cirrhosis due to hepatitis B; LC-C: LC-C:liver cirrhosis due to hepatitis C; 
HCC, hepatocellular carcinoma; tPA, tissue-type plasminogen activator
Table 4.  Arterial anastomosis and complications in living donor liver transplantation
Primary anastomosis
Anatomical anastomosis 65 (89.1%) 






Saphenous vein 1 (converted after rupture)
Complications 6 (8%) Re-anastomosis
Rupture 1 Anatomical 1 (after intimal dissection)
HAT 3 Non anatomical 4 
Intimal dissection 1 RGEA 2 (after HAT)
Stenosis 1 Saphenous vein 1 (after rupture)
Ao- SpA-radialA 1 (after HAT, died)
RGEA, right gastroepiploic artery; HAT, hepatic arterial thrombus; LGA, left hepatic artery,
HA, hepatic artery; SpA, splenic artery; radialA, radial artery; Ao, Aorta
Table 5.  Biliary reconstruction and complications after living donor liver transplantation
Reconstruction methods
Duct-to-Duct 53 (72.6%) Adult 52
Pediatric 1
Hepaticojejunostomy 20 (27.4%) Adult 12
Pediatric 8
Biliary complications 14 (19.1%)
Anastomotic stricture 10 (D-D 10, H-J 0)
Bile leak from cut surface 1 (H-J 1)
Bile leak at anstomosis 3 (D-D 1, H-J 2)
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Fig. 2. Changes in relationship between donor and recipient in LDLT
Aug, 1997 – Dec, 2003
(n=28)
Jan, 2004 – Jul, 2007
(n=45)











































64         42                     24                      12    
Children
9           6                       4                         0
p=0.093
